Clinical Evaluation of Meropenem-Vaborbactam Combination for the Treatment of Urinary Tract Infection: Evidence to Date

References

• Gajdács M, Albericio F. Antibiotic resistance: from bench to patients. Antibiotics (Basel). 2019;8(3):129. doi:10.3390/antibiotics8030129
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (US). Antibiotic Resistance Threats in the United States, 2019. Centers for Disease Control and Prevention (US); 2019. Available from: https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf. Accessed February 27, 2021.
   Google Scholar
• Behzadi P, Urbán E, Matuz M, Benkő R, Gajdács M. The role of gram-negative bacteria in urinary tract infections: current concepts and therapeutic options. Adv Exp Med Biol. 2021;1323:35–69. doi:10.1007/5584_2020_566
   PubMed Web of Science ®Google Scholar
• O’Neill J. Tackling drug-resistant infections globally: final report and recommendations. London: HM Government and Wellcome Trust; 2016. Review on Antimicrobial Resistance, chaired by Jim O’Neill. Available from: https://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf. Accessed February 27, 2021.
   Google Scholar
• Jacoby GA, Munoz-Price LS. The new beta-lactamases. N Engl J Med. 2005;352(4):380–391. doi:10.1056/NEJMra041359
   PubMed Web of Science ®Google Scholar
• Rubino CM, Bhavnani SM, Loutit JS, et al. Phase 1 study of the safety, tolerability, and pharmacokinetics of vaborbactam and meropenem alone and in combination following single and multiple doses in healthy adult subjects. Antimicrob Agents Chemother. 2018;62(4):e02228–17. doi:10.1128/AAC.02228-17
   PubMed Web of Science ®Google Scholar
• Vabomere® (meropenem and vaborbactam) [package insert]. In the Treatment of Cutiarm Yourself for Battle Against Serious Gram-Negative Pathogens with Vabomere^®1*. Lincolnshire, IL: Melinta Therapeutics, Inc.; 2021.
   Google Scholar
• World Health Organization (WHO). Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics; 2021. Available from: https://www.who.int/medicines/publications/global-priority-list-antibiotic-resistant-bacteria/en/. Accessed January 25, 2021.
   Google Scholar
• Castanheira M, Huband MD, Mendes RE, Flamm RK. Meropenem-vaborbactam tested against contemporary gram-negative isolates collected worldwide during 2014, including carbapenem-resistant, KPC-producing, multidrug-resistant, and extensively drug-resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2017;61(9):e00567–17. doi:10.1128/AAC.00567-17
   PubMed Web of Science ®Google Scholar
• Codjoe FS, Donkor ES. Carbapenem resistance: a review. Med Sci (Basel). 2017;6(1):1. doi:10.3390/medsci6010001
   PubMedGoogle Scholar
• Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. Carbapenems: past, present, and future. Antimicrob Agents Chemother. 2011;55(11):4943–4960. doi:10.1128/AAC.00296-11
   PubMed Web of Science ®Google Scholar
• Kohler J, Dorso KL, Young K, et al. In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum β-lactamase- and extended-spectrum β-lactamase- producing K. pneumoniae and E. coli clinical isolates. Antimicrob Agents Chemother. 1999;43:1170–1176. doi:10.1128/AAC.43.5.1170
   PubMed Web of Science ®Google Scholar
• Yang Y, Bhachech N, Bush K. Biochemical comparison of imipenem, meropenem and biapenem: permeability, binding to penicillin-binding proteins, and stability to hydrolysis by beta-lactamases. J Antimicrob Chemother. 1995;35(1):75–84. doi:10.1093/jac/35.1.75
   PubMed Web of Science ®Google Scholar
• Hecker SJ, Reddy KR, Totrov M, et al. Discovery of a cyclic boronic acid b-lactamase inhibitor (RPX7009) with utility vs Class A serine carbapenemases. J Med Chem. 2015;58(9):3682–3692. doi:10.1021/acs.jmedchem.5b00127
   PubMed Web of Science ®Google Scholar
• Lomovskaya O, Sun D, Rubio-Aparicio D, et al. Vaborbactam: spectrum of beta-lactamase inhibition and impact of resistance mechanisms on activity in Enterobacteriaceae. Antimicrob Agents Chemother. 2017;61(11):e01443–17. doi:10.1128/AAC.01443-17
   PubMed Web of Science ®Google Scholar
• Castanheira M, Rhomberg PR, Flamm RK, Jones RN. Effect of the β-lactamase inhibitor vaborbactam combined with meropenem against serine carbapenemase-producing enterobacteriaceae. Antimicrob Agents Chemother. 2016;60(9):5454–5458. doi:10.1128/AAC.00711-16
   PubMed Web of Science ®Google Scholar
• Lapuebla A, Abdallah M, Olafisoye O, et al. Activity of meropenem combined with RPX7009, a novel β-lactamase inhibitor, against Gram-negative clinical isolates in New York City. Antimicrob Agents Chemother. 2015;59(8):4856–4860. doi:10.1128/AAC.00843-15
   PubMed Web of Science ®Google Scholar
• Castanheira M, Doyle TB, Kantro V, Mendes RE, Shortridge D. Activity of meropenem-vaborbactam and characterization of carbapenem resistance mechanisms among carbapenem-resistant enterobacteriaceae from United States hospitals (2016–2017). Poster presented at the: 4th ASM Microbe Conference; June 2019; San Francisco, CA.
   Google Scholar
• Shortridge D, Deshpande L, Duncan L, Streit J, Castanheira M. Activity of meropenem-vaborbactam and single-agent comparators against Enterobacterales isolates, including KPC-producing isolates, from European patients hospitalized with pneumonia including ventilator-associated pneumonia (2014–2019). Poster presented at the: ID Week 2020; October 2020; Virtual Conference.
   Google Scholar
• Shortridge D, Deshpande L, Doyle T, Streit J, Castanheira M. Activity of meropenem-vaborbactam and comparators against globally disseminated Klebsiella pneumoniae sequence type 258. Poster presented at the: ID Week 2020; October 2020; Virtual Conference.
   Google Scholar
• Lomovskaya O, Tsivkovski R. Vaborbactam (RPX7009) plus meropenem is active against the newly discovered BKC-1 and FRI-1 carbapenemases. Poster presented at the: 26th Annual European Congress of Clinical Microbiology and Infectious Diseases; April 2016; Amsterdam, Netherlands.
   Google Scholar
• Sun D, Rubio-Aparicio D, Nelson K, Dudley MN, Lomovskaya O. Meropenem-vaborbactam resistance selection, resistance prevention, and molecular mechanisms in mutant of KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2017;61(12):e01694–17. doi:10.1128/AAC.01694-17
   PubMed Web of Science ®Google Scholar
• Rubio-Aparicio D, Loutit J, Dudley M, Lomovskaya O. Potency of meropenem-vaborbactam in lung surfactant. Antimicrob Agents Chemother. 2017;62(1):e01702–17. doi:10.1128/AAC.01702-17
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 30th. In: CLSI Guideline M100-Ed30. Wayne, PA: Clinical and Laboratory Standards Institute; 2020.
   Google Scholar
• Griffith D, Rubino C, Loutit J, Morgan E, White D, Dudley M. A phase 1 study of the safety, tolerability, and pharmacokinetics of the β-lactamase inhibitor RPX7009 alone, meropenem alone, and both in combination (Carbavance) TID for 7 days in healthy adult subjects. Open Forum Infect Dis. 2014;1(S1):S154–155. doi:10.1093/ofid/ofu052.267
   Google Scholar
• Griffith D, Loutit J, Morgan E, et al. Phase 1 study of the safety, tolerability, and pharmacokinetics of the beta-lactamase inhibitorRPX7009 in healthy adult subjects. Antimicrob Agents Chemother. 2016;60(10):6326–6332. doi:10.1128/AAC.00568-16
   PubMed Web of Science ®Google Scholar
• Wenzler E, Gotfried MH, Loutit JS, et al. Meropenem-RPX7009 concentrations in plasma, epithelial lining fluid, and alveolar macrophages of healthy adult subjects. Antimicrob Agents Chemother. 2015;59(12):7232–7239. doi:10.1128/AAC.01713-15
   PubMed Web of Science ®Google Scholar
• Coves-Orts FJ, Borras-Blasco J, Navarro-Ruiz A, Murcia-López A, Palacios-Ortega F. Acute seizures due to a probable interaction between valproic acid and meropenem. Ann Pharmacother. 2005;39(3):533–537. doi:10.1345/aph.1E358
   PubMed Web of Science ®Google Scholar
• De Turck BJG, Diltoer MW, Cornelis PJ, et al. Lowering of plasma valproic acid concentrations during concomitant therapy with meropenem and amikacin. J Antimicrob Chemother. 1998;42(4):563–564. doi:10.1093/jac/42.4.563
   PubMed Web of Science ®Google Scholar
• Haroutiunian S, Ratz Y, Rabinovich B, Adam M, Hoffman A. Valproic acid plasma concentration decreases in a dose-independent manner following administration of meropenem: a retrospective study. J Clin Pharmacol. 2009;49(11):1363–1369. doi:10.1177/0091270009334377
   PubMed Web of Science ®Google Scholar
• Nacarkucuk E, Saglam H, Okan M. Meropenem decreases serum level of valproic acid. Pediatr Neurol. 2004;31(3):232–234. doi:10.1016/j.pediatrneurol.2004.03.014
   PubMed Web of Science ®Google Scholar
• Spriet I, Goyens J, Meersseman W, Wilmer A, Willems L, Van Paesschen W. Interaction between valproate and meropenem: a retrospective study. Ann Pharmacother. 2007;41(7–8):1130–1136. doi:10.1345/aph.1K079
   PubMed Web of Science ®Google Scholar
• Craig WA, Ebert S, Watanabe Y. Differences in time above MIC (T > MIC) required for efficacy of β-lactams in animal infection T 1 MIC models [abstract 86]. In: Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans). Washington, DC: American Society for Microbiology; 1993.
   Google Scholar
• Ong CR, Tessier PR, Li C, Nightingale CH, Nicolau DP. Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps. Diagn Microbiol Infect Dis. 2007;57(2):153–161. doi:10.1016/j.diagmicrobio.2006.06.014
   PubMed Web of Science ®Google Scholar
• Mattoes HM, Kuti JL, Drusano GL, Nicolau DP. Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem. Clin Ther. 2004;26(8):1187–1198. doi:10.1016/s0149-2918(04)80001-8
   PubMed Web of Science ®Google Scholar
• Maglio D, Banevicius MA, Sutherland C, Babalola C, Nightingale CH, Nicolau DP. Pharmacodynamic profile of ertapenem against Klebsiella pneumoniae and Escherichia coli in a murine thigh model. Antimicrob Agents Chemother. 2005;49(1):276–280. doi:10.1128/AAC.49.1.276-280.2005
   PubMed Web of Science ®Google Scholar
• Griffith D, Sabet M, Tarazi Z, Lomovskaya O, Dudley MN. Pharmacokinetics/pharmacodynamics of vaborbactam, a novel beta-lactamase inhibitor, in combination with meropenem. Antimicrob Agents Chemother. 2019;63(1):e01659–18. doi:10.1128/AAC.01659-18
   PubMed Web of Science ®Google Scholar
• Sabet M, Tarazi Z, Nolan T, et al. Activity of meropenem-vaborbactam in mouse models of infection due to KPC-producing carbapenem-resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2017;62(1):e01446–17. doi:10.1128/AAC.01446-17
   PubMed Web of Science ®Google Scholar
• Sabet M, Tarazi Z, Rubio-Aparicio D, et al. Activity of simulated human dosage regimens of meropenem and vaborbactam against carbapenem- resistant Enterobacteriaceae in an in vitro hollow-fiber model. Antimicrob Agents Chemother. 2018;62(2):e01969–17. doi:10.1128/AAC.01969-17
   PubMed Web of Science ®Google Scholar
• Bhavnani SM, Trang M, Griffith DC, et al. Meropenem-vaborbactam pharmacokinetic pharmacodynamic target attainment analyses as support for dose selection in patients with normal renal function and varying degrees of renal impairment. Poster presented at the: 6th Annual ID Week; October 2017; San Diego, CA.
   Google Scholar
• Kaye KS, Bhowmick T, Metallidis S, et al. Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial. JAMA. 2018;319(8):788–799. doi:10.1001/jama.2018.0438
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration (FDA). Complicated urinary tract infections: developing drugs for treatment: guidance for industry; 2021. Available from: https://www.fda.gov/downloads/Drugs/Guidances/ucm070981.pdf. Accessed February 27, 2021.
   Google Scholar
• European Medicines Agency (EMA). Addendum to the guideline on the evaluation of medicinal products indicated for treatment of bacterial infections; 2021. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/11/WC500153953.pdf. Accessed February 27, 2021.
   Google Scholar
• FDA. FDA medical review: vabomere (meropenem and vaborbactam), 2017. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209776Orig1s000MedR.pdf. Accessed February 27, 2021.
   Google Scholar
• Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, et al. Effect and safety of meropenem–vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: the TANGO II randomized clinical trial. Infect Dis Ther. 2018;7:439–455. doi:10.1007/s40121-018-0214-1
   PubMed Web of Science ®Google Scholar
• Wunderink R, Giamarellos-Bourboulis EJ, Rahav G, et al. Meropenem-vaborbactam (VABOMERE) vs. best available therapy for carbapenem-resistant Enterobacteriaceae infections in TANGO II: primary outcomes by site of infection. Poster presented at the: 6th Annual ID Week; October 2017; San Diego, CA.
   Google Scholar
• Bassetti M, Giacobbe DR, Patel N, Tillotson G, Massey J. Efficacy and safety of meropenem–vaborbactam versus best available therapy for the treatment of carbapenem-resistant enterobacteriaceae infections in patients without prior antimicrobial failure: a post hoc analysis. Adv Ther. 2019;36(7):1771–1777. doi:10.1007/s12325-019-00981-y
   PubMed Web of Science ®Google Scholar
• Alosaimy S, Jorgensen SCJ, Lagnf AM et al. Meropenem vaborbactam in patients with carbapenem resistant enterobacteriaceae gram-negative bloodstream infection: a case series. Poster presented at the: 22nd Annual MAD-ID Meeting; May 2019; Orlando, FL.
   Google Scholar
• Ge IY, Fevrier HB, Conell C. reducing risk of clostridium difficile infection and overall use of antibiotic in the outpatient treatment of urinary tract infection. Ther Adv Urol. 2018;10:283–293. doi:10.1177/1756287218783871
   PubMed Web of Science ®Google Scholar
• Avycaz® [package insert]. Verona, Italy: ACS Dobfar S.p.A.; 2022.
   Google Scholar
• Zerbaxa® [package insert]. Rahway, NJ: Merck Sharp & Dohme LLC; 2022.
   Google Scholar
• Ackley R, Roshdy D, Meredith J, et al. Meropenem-vaborbactam vs ceftazidime-avibactam for treatment of carbapenem-resistant Enterobacteriaceae infections. Antimicrob Agents Chemother. 2020;64(5):e02313–19. doi:10.1128/AAC.02313-19
   PubMed Web of Science ®Google Scholar
• Wang B, Wu P, Kwan B, Tu XM, Feng C. Simpson’s paradox: examples. Shanghai Arch Psychiatry. 2018;30(2):139–143. doi:10.11919/j.issn.1002-0829.218026
   PubMedGoogle Scholar
• Jancel T, Dudas V. Management of uncomplicated urinary tract infections. West J Med. 2002;176(1):51–55. doi:10.1136/ewjm.176.1.51
   PubMedGoogle Scholar
• Gajdács M, Bátori Z, Ábrók M, Lázár A, Burián K. Characterization of resistance in gram-negative urinary isolates using existing and novel indicators of clinical relevance: a 10-year data analysis. Life (Basel). 2020;10(2):16. doi:10.3390/life10020016
   PubMed Web of Science ®Google Scholar
• European Committee on Antimicrobial Susceptibility Testing (EUCAST). EUCAST criteria; 2021. Available from: http://www.eucast.org/. Accessed January 25, 2021.
   Google Scholar
• Recarbrio® [package insert]. Rahway, NJ: Merck Sharp & Dohme LLC; 2022.
   Google Scholar
• Hackel MA, Lomovskaya O, Dudley MN, et al. In vitro activity of meropenem-vaborbactam against clinical isolates of KPC-positive Enterobacteriaceae. Antimicrob Agents Chemother. 2018;62(1):e01907–17. doi:10.1128/AAC.01904-17
   PubMed Web of Science ®Google Scholar
• Castanheira M, Woosley LN, Huband MD, Flamm RK. Activity against Enterobacteriaceae isolates, including carbapenem-resistant and carbapenemase-producing isolates, collected in United States (US) hospitals during 2016. Poster presented at the: 21st Annual MAD-ID Meeting; May 2018; Orlando, FL.
   Google Scholar
• Doi Y. Treatment options for carbapenem-resistant gram-negative bacterial infections. Clin Infect Dis. 2019;69(Suppl 7):S565–S575. doi:10.1093/cid/ciz830
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Bhowmick T, Darouiche RO, et al. Per pathogen outcomes of meropenem-vaborbactam (M-V) versus piperacillin-tazobactam (P-T) in the treatment of adults with complicated urinary tract infections (cUTI), including acute pyelonephritis (AP), in TANGO 1, a phase 3 randomized, double-blind, double-dummy trial. Poster presentated at the: 27th Annual European Congress of Clinical Microbiology and Infectious Diseases. Apr 2019; Vienna, Austria.
   Google Scholar